# Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer

Source: https://onco.cc/trials/nct05367440/  
OnCo record `nct05367440` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

This study tests a PARP inhibitor; the registry reports that it is active not recruiting.

## Summary

The registry lists NCT05367440 as active not recruiting, last updated 2026-08-26. Enrolment is 174 actual participants. Interventions: AZD5305, Enzalutamide, Abiraterone Acetate, Darolutamide, Apalutamide. Primary measures include Number of patients with Adverse Events and Serious Adverse Events; Part A: Number of patients with Dose Limiting Toxicities (DLTs). No results are posted in the registry; this does not exclude separate publications.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-10-06
- Also known as: PETRANHA
- Tags: ctgov-ingest
- Registry id: NCT05367440
- Phase: 1/2
- Setting: A Multi-arm, Open-label Phase I/IIa Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of AZD5305 in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer (PETRANHA)
- Sponsor: AstraZeneca
- Enrolled: 174

## Sources

- ClinicalTrials.gov NCT05367440: https://clinicaltrials.gov/study/NCT05367440

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- targets: [PARP](https://onco.cc/targets/parp/)
- drugs: [Abiraterone acetate](https://onco.cc/drugs/abiraterone/), [Apalutamide](https://onco.cc/drugs/apalutamide/), [Darolutamide](https://onco.cc/drugs/darolutamide/), [Enzalutamide](https://onco.cc/drugs/enzalutamide/), [Saruparib](https://onco.cc/drugs/saruparib/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)

---
JSON: https://onco.cc/api/v1/entities/nct05367440.json